scholarly journals Golimumab in the treatment of extra-skeletal manifestations of ankylosing spondylitis

2019 ◽  
Vol 13 (4) ◽  
pp. 110-115
Author(s):  
A. B. Demina

Extra-skeletal manifestations (EMs) of ankylosing spondylitis (AS) can occur and proceed in parallel with inflammatory changes in the joints and spine and often dominate in the clinical picture of AS, determining its high activity and significantly worsening the quality of life in patients. In a number of cases, EMs are characterized by an insufficient response to standard anti-inflammatory therapy for back pain, arthritis, and enthesitis; and there is a need to prescribe another class of drugs.The review highlights the results of studies evaluating the efficacy of golimumab (GLM) in treating EMs in patients with AS: uveitis (GO-EASY Study) and ulcerative colitis (UC) (PURSUIT-SC, PURSUIT-M studies). Analysis of these studies have shown the high efficacy and safety of GLM in reducing the clinical manifestations of AS and in preventing the exacerbations of uveitis and UC. However, despite the successes achieved in treating AS and its EMs, there are many unresolved issues, including those related to the elaboration of optimal treatment regimens, which required longer observational studies with a large sample size.

Author(s):  
Kimberly Chow ◽  
Lauren Koranteng

Constipation, diarrhea, and bowel obstruction are three common and distressing symptoms in palliative care patients. These symptoms rarely occur without other clinical manifestations of disease, and their management must be considered in light of comorbid disease. Constipation, diarrhea, and bowel obstruction affect a person’s quality of life, eligibility for certain therapies, and may even be life-threatening. This chapter discusses the advanced practice registered nurse (APRN)’s role in the assessment, prevention, and management of these common bowel symptoms. as well as the global issues surrounding management. The causes and pharmacological treatment of these three bowel symptoms are discussed and detailed medication treatment regimens are presented in tabular form.


2019 ◽  
Vol 1 (18) ◽  
pp. 6-12
Author(s):  
A. R. Babaeva ◽  
E. V. Kalinina ◽  
M. S. Zvonorenko ◽  
E. V. Shcherbinina ◽  
I. V. Bramnik

The article presents current data on algorithms for managing patients with the most common forms of spondylarthritis — ankylosing spondylitis, axial spondylarthritis and psoriatic arthritis, based on existing national and European recommendations. The analysis of innovative approaches to the patho‑genetic therapy of spondyloarthritis with special attention to the inhibition of interleukin‑17 using the drug secukinumab. Along with the literature data, there is a clinical experience of using secukinumab in patients with ankylosing spondylitis, axial spondyloarthritis, and psoriatic arthritis. It has been shown that secukinumab can improve the quality of treatment and achieve clinical remission in patients with high disease activity and adverse prognostic factors. In connection with the high efficacy and safety of treatment, the feasibility of using secukinumab as a first‑line biological agent with insufficient response to a standard basic drug is discussed.


2021 ◽  
pp. 42-47
Author(s):  
Yu. N. Maksimov ◽  
D. Kh. Khaibullina ◽  
F. I. Devlikamova

Introduction. Radiculopathy is one of the causes of neuropathic pain. Among the causes of back pain, lumbar radiculopathy ranks second after non-specific musculoskeletal pain. Patients with radiculopathy have a marked decrease in the quality of life, a tendency to disability, which causes a large amount of diagnostic and therapeutic measures and associated economic losses. There is no unified view on the pathogenesis of radiculopathy, and the pain syndrome includes neuropathic and nociceptive components. The proposed treatment regimens for radiculopathy differ and are of a recommendatory nature.The purpose of the retrospective observational study was to study the effectiveness of the drug Neurobion® in the complex therapy of radiculopathy.Materials and methods. The study of outpatient records of 120 patients aged 25–65 years, suffering from lumbosacral radiculopathy was performed. The patients were divided into 2 groups and received basic therapy, which included NSAIDs, simple analgesics, muscle relaxants, and anticonvulsants. Patients of group 1 additionally received the drug Neurobion®.Results and discussion. Faster regression of clinical manifestations was observed in group 1 patients. The results of treatment in group 1 patients were higher both in terms of subjective feelings and objective criteria. The presence of two medicinal forms of Neurobion® allows a personalized approach to the patient’s therapyConclusions. The use of the drug Neurobion® is pathogenetically justified in the treatment of radiculopathy, provides earlier positive dynamics of subjective feelings of patients and objective indicators, improves the quality of life, leads to shorter treatment periods, reducing economic costs. The effectiveness and good tolerability of the drug Neurobion® allow us to recommend it for inclusion in the complex therapy of radiculopathy. 


2019 ◽  
Vol 20 (8) ◽  
pp. 1898 ◽  
Author(s):  
Alessandra Bettiol ◽  
Giuseppe Lopalco ◽  
Giacomo Emmi ◽  
Luca Cantarini ◽  
Maria Letizia Urban ◽  
...  

Autoinflammatory diseases (AIDs) are heterogeneous disorders characterized by dysregulation in the inflammasome, a large intracellular multiprotein platform, leading to overproduction of interleukin-1(IL-1)β that plays a predominant pathogenic role in such diseases. Appropriate treatment is crucial, also considering that AIDs may persist into adulthood with negative consequences on patients’ quality of life. IL-1β blockade results in a sustained reduction of disease severity in most AIDs. A growing experience with the human IL-1 receptor antagonist, Anakinra (ANA), and the monoclonal anti IL-1β antibody, Canakinumab (CANA), has also been engendered, highlighting their efficacy upon protean clinical manifestations of AIDs. Safety and tolerability have been confirmed by several clinical trials and observational studies on both large and small cohorts of AID patients. The same treatment has been proposed in refractory Kawasaki disease, an acute inflammatory vasculitis occurring in children before 5 years, which has been postulated to be autoinflammatory for its phenotypical and immunological similarity with systemic juvenile idiopathic arthritis. Nevertheless, minor concerns about IL-1 antagonists have been raised regarding their employment in children, and the development of novel pharmacological formulations is aimed at minimizing side effects that may affect adherence to treatment. The present review summarizes current findings on the efficacy, safety, and tolerability of ANA and CANA for treatment of AIDs and Kawasaki vasculitis with a specific focus on the pediatric setting.


2020 ◽  
Vol 58 (3) ◽  
pp. 268-275
Author(s):  
E. Yu. Loginova ◽  
Yu. L. Korsakova ◽  
E. E. Gubar ◽  
P. L. Karpova ◽  
T. V. Korotaeva

Objective: to evaluate the clinical efficacy and safety of the targeted synthetic disease-modifying anti-rheumatic drug (DMARD) tofacitinib (TOFA; Yakvinus®) in patients with active psoriatic arthritis (PsA) at 12 and 24 weeks after starting treatment. To define the place of TOFA in the therapy of PsA patients. Subjects and methods. Examinations were made in 41 patients (17 men and 24 women) with active PsA and an insufficient response to previous treatment with synthetic DMARDs and/or biological agents (BA). Before starting therapy, the median disease activity for psoriatic arthritis (DAPSA) and disease activity score (DAS28) were 44.2 [37.8; 55.3] and 5.5 [4.7; 6.1], respectively. TOFA tablets were prescribed at a dose of 5 mg twice daily for 24 weeks with possible dose escalation to 10 mg twice daily after 12 weeks. At the beginning of the investigation, at 12 and 24 weeks, the investigators assessed disease activity and TOFA therapy efficiency of according to DAPSA, DAS28 and minimal disease activity (MDA) criteria: tender joint count ≤1, swollen joint count ≤1, a psoriasis area severity index (PASI) ≤1 or body surface area (BSA) ≤3%, pain intensity ≤15 mm, patient global assessment ≤20 mm, Health Assessment Questionnaire (HAQ) ≤0.5, and enthesitis ≤1. They also determined the number of patients who had achieved remission (DAPSA ≤4, DAS28 score <2.6), low disease activity (DAPSA 5-14, ≤2.6, DAS28 <3.2) or MDA (5 out of the 7 criteria) during TOFA therapy at 24-week follow-up. The safety of therapy was evaluated by analyzing the drug-induced adverse events (AE): the frequency, severity and time of their occurrence were studied. Results and discussion. At 24 weeks after initiation of TOFA therapy, there was a significant decrease of median DAPSA and DAS28 values as compared to baseline, to 11 [4.3; 17.3] and 2.6 [1.7; 3.4] respectively. The median Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) also significantly decreased from 6 [4.2; 7] and 3.8 [2.8; 4.4] to 1.4 [0.6; 3.2] and 1.5 [1; 2.1] respectively. The median BSA was significantly reduced from 3 [1; 5] to 0.5 [0.1; 2]. At 24 weeks after initiation of TOFA therapy, DAPSA and DAS28 low disease activity/remission were achieved by 38.5/23.1% and 17.9/53.9% of patients, respectively. Fifteen (38.5%) patients achieved MDA. 38 (92.7%) of the 41 patients completed a full TOFA therapy cycle. Two patients dropped out of the investigation due to ineffective therapy and one due to AE (diarrhea occurring up to 10 times daily, headache, elevated blood pressure, and lacrimation). At 24 weeks, 14 (34.2%) patients reported to have AE. The most common AE noted in 7 (17.1%) patients were infections: acute respiratory viral infection (n=3), fever (n=2), and folliculitis (n=2). In addition, two patients had diarrhea and two had headache. Conclusion. TOFA is an effective drug for the treatment of PsA patients with moderate or high inflammatory activity, has a significant effect on all clinical manifestations of PsA and has a satisfactory safety profile.


2019 ◽  
Vol 10 (Vol.10, No.3) ◽  
pp. 278-287
Author(s):  
Alexander Andreev ◽  
Sergey Puhlik ◽  
Oleg Melnikov ◽  
Irina Tagunova ◽  
Sergey Gushcha

Introduction: The component of the lymphopharyngeal ring is the lingual tonsil (LT), located on the root of the tongue. With pathological changes in the lymphoid tissue of the pharynx, surgical removal of the tonsils, as a result of increased antigenic load, a compensatory increase in LT is observed – «lingual tonsillar hypertrophy». This is observed against the background of age-related involutive changes, when the remaining elements of the lymphopharyngeal ring begin to perform anti-antigenic and adaptive activity. The processes taking place in, the structure of the LT, which is familiar to the body, changes - the receptor apparatus creates pathological impulses from the organ. The severity of clinical manifestations correlates with the degree of increase in LT. The emphasis on these manifestations, psychosomatic conditions, create a complex of pathological sensations that violate the quality of patients’ life. The goal and objectives of the study are aimed at improving the quality of patients’ life with lingual tonsil hypertrophy (LTH), by developing effective methods of diagnosis and treatment, assessing the role of the immunoregulatory shift in the pathogenesis of LTH of the possibility of their correction by the action of a physical factor (cold destruction). Materials and methods: When examining 850 people who underwent complex research and instrumental diagnostics in connection with the pathology of ENT organs, 119 people (the main group) were diagnosed with different degrees of LTH, with control of 30 healthy people. Cryosurgical treatment was offered to 76 patients who used the method for treating of lingual tonsil hypertrophy by cryodestruction using a hook-shaped applicator with a heat-insulating nozzle on the back surface, an individual polyethylene cap, and a cryoapparatus. Results and discussions: With LTH, an increase in the volume and mass of tissues forming the morphological basis of the tonsil was detected: the main substance was an increase in the number and size of layers of coarse fibrous fibers, fields of fat cells, and the growth of mucous glands. The mucous membrane, thinning, undergoes dystrophic-degenerative changes. The rate of proliferation correlates with the severity of inflammation, the causes of which are multifactorial, individual. There is an increased sensitivity reaction to microbial and household allergens, an increase in the content of antibodies in the blood to LT tissues, a change in microbiocinosis of the pharyngeal mucosa, and vegetation of non-resident microflora. As a result of cryosurgical treatment in 56 (73.68%) cases, a decrease in the volume of LT tissue was observed. The deep layers, partially absorbed, were replaced by healthy tissues, the surface layers were rejected with the formation of an atrophic scar or regenerate, the structure of which was close to organotypic. The cause of pathological impulse was eliminated, clinical indicators were normalized, the quality of life of patients was improved. Conclusions: LTH should be considered as a continuation of the development of a productive process associated with immunoregulatory changes in chronic infectious and allergic conditions. Local cryogenicity on LTH was accompanied by normalization of the structure of its own substance, LT, and a decrease in inflammatory changes in surrounding tissues. The development of inflammatory changes in LT was a local manifestation of a general disturbance in the functioning of the immune defense system. Achieving a persistent positive effect in the treatment of LTH requires an integrated approach with mandatory systemic immune correction and hormonal correction.


2021 ◽  
pp. 106-121
Author(s):  
Joeseph Nenow ◽  
Esthe Balogh ◽  
Steven Feldman

Psoriasis is a chronic inflammatory skin condition that impacts patients’ quality of life and has large economic consequences. While current biologics are remarkable for their efficacy and safety, opportunities for improvement exist due to their rare side effects, fading efficacy, method of delivery, and expense. Biologics such as bimekizumab offer high likelihood of clearance, while oral options (e.g., deucravacitinib) allow patients to avoid injections and achieve efficacies similar to adalimumab or ustekinumab. As a result, there is limited room for the development of new biologics. Several oral therapies such as the oral monoclonal microbial EDP1815 have the potential to meet patient expectations for efficacy and convenient administration. However, emerging treatment regimens for plaque psoriasis will increasingly require a multimodal approach, addressing patient adherence, lifestyle choices, and awareness of the individual’s underlying pathophysiological processes. In this narrative review, the authors discuss recent advances in the development of biologic and oral small molecules for plaque psoriasis.


2019 ◽  
pp. 52-57
Author(s):  
O. N. Minushkin ◽  
L. V. Maslovsky ◽  
M. I. Bulanova ◽  
O. F. Shaposhnikovа

A study of the clinical efficacy and safety of the drug Samelix (ademetionine, manufacturer – JSC «Canonfarma production», Russia) in 30 patients with chronic alcoholic liver disease (steatohepatitis mild to moderate currents, cirrhosis of the liver grade a ChildPugh) with the syndrome of cholestasis. Purpose of the study: evaluate the clinical efficacy and safety of Samelix (ademetionine) in 30 patients with chronic alcoholic liver disease. Objectives of the study: evaluate the effect of the drug on biochemical parameters, evaluate the effect of the drug on the clinical manifestation of the disease based on the individual diary data during the course therapy, assess the quality of life through the SF-36 questionnaire before and after treatment; report adverse events. The results of the study showed that therapy with this drug leads to a significant positive dynamics of biochemical parameters, regression of clinical manifestations of the disease, a significant increase in the quality of life. Good and excellent results of therapy were observed in 76.7% of cases. The drug is safe and well tolerated.


2013 ◽  
Vol 73 (3) ◽  
pp. 587-594 ◽  
Author(s):  
Feng Huang ◽  
Jieruo Gu ◽  
Ping Zhu ◽  
Chunde Bao ◽  
Jianhua Xu ◽  
...  

Background and objectivesEfficacy of adalimumab for ankylosing spondylitis (AS) has been established for Western populations but not in the Chinese population. This study is the first to evaluate the efficacy and safety of adalimumab in Chinese patients with AS.MethodsChinese adults with active AS who had an inadequate response or were intolerant to ≥1 non-steroidal anti-inflammatory drugs were randomised to adalimumab 40 mg (N=229) or matching placebo (N=115) subcutaneously every other week (EOW) for 12 weeks, followed by a 12-week open-label adalimumab 40 mg EOW phase. The primary efficacy endpoint was the percentage of patients meeting the Assessment in Spondyloarthritis International Society (ASAS20) response criteria at week 12. The recently developed AS Disease Activity Score (ASDAS), as well as efficacy measures of spinal mobility, disease activity, physical function and quality of life were evaluated.ResultsAt week 12, adalimumab treatment resulted in a significantly greater percentage of ASAS20 responders than placebo (67.2% versus 30.4%, respectively; p<0.001). Differences in ASAS20 were observed as early as week 2 (42.8% vs 6.1%, respectively; p<0.001). The percentages of patients achieving ASAS40, ASAS 5/6 and ASDAS inactive disease were significantly greater with adalimumab than placebo at week 12 (all p<0.001). Tuberculosis was reported in one patient. No cases of malignancy, lymphoma, demyelinating disease or lupus-like syndrome were reported during the study.ConclusionsAdalimumab significantly reduced the signs and symptoms, improved physical function and quality of life of Chinese patients with active AS, and was generally safe and well tolerated in this population.


2021 ◽  
Vol 3 (1) ◽  
pp. 374-385

Coronavirus 2019 (COVID-19), is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first reported in December 2019. The plasma markers of coagulation, like D-dimers and elevated prothrombin time (PT) are higher in patients with COVID-19. The administration of anticoagulant is beneficial in those patients. Heparins have many therapeutic functions that are important for the controlling of COVID-19-associated clinical manifestations like, neutralization of inflammatory mediators and neutralization of extracellular cytotoxic histones. Many observational studies in different countries have been done and large number of clinical trials have been designed and registered to evaluate efficacy and safety of heparin for patients with COVID-19. The aim of this narrative review is to summarize all available data from previously published studies concerning the use of heparin in treatment of the COVID-19 pandemic.


Sign in / Sign up

Export Citation Format

Share Document